Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation

Background/Aim

The optimal therapeutic strategy for patients with non-small-cell lung cancer (NSCLC) harboring the BRAF non-V600E mutation has yet to be established. LY3009120, a novel pan-RAF inhibitor, has demonstrated significant antitumor activity across various BRAF genotypes. This study aimed to investigate the antitumor effects of LY3009120 specifically in NSCLC cells with the BRAF non-V600E mutation.

Materials and Methods

We assessed the antitumor effects of LY3009120 using MTS assays and flow cytometry, and analyzed protein expression through Western blotting. In vivo experiments were conducted using mouse xenograft models.

Results

LY3009120 effectively suppressed downstream pathway molecules associated with BRAF and induced cleavage of poly ADP-ribose polymerase in all NSCLC cell lines tested. Additionally, LY3009120 inhibited tumor growth in vivo in NSCLC cells with the BRAF non-V600E mutation.

Conclusion

LY3009120 is a promising therapeutic option for patients with BRAF non-V600E mutant NSCLC.